Lynda Charters

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

Stuart Therapeutics Inc. submitted an investigational NDA amendment to the FDA to study ST-100 (vezocolmitide) in corneal wound healing.

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

• The American Academy of Ophthalmology 2026 annual meeting is set for October 9-12 in New Orleans.

Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.

Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Patient enrollment is complete in the the ASTRA phase 3 study AURN001 to treat corneal edema associated with corneal endothelial dysfunction.

Subretinal deposits are linked to worse surgical risks in patients with severe aortic stenosis and reduced systemic blood flow.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Q3 2026 delivered advances in some closely watched pipeline products.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Women are more often affected than men, and the disease manifests differently between the sexes.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.

Researchers from China and Singapore found that the macular microvasculature is altered as early as the pre-diabetic stage of the disease. The findings suggest that the status of the choriocapillaris can be used to monitor early metabolic disease.

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Alice Epitropoulos, MD, shares cases of Demodex blepharitis and reflects on how lotilaner has changed treatment before ocular surgery.